Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tiny electric zap help tame fatty liver?

NCT ID NCT07200934

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether adding a mild electrical stimulation device (TENS) to a Mediterranean diet can help people with nonalcoholic fatty liver disease feel less hungry and improve their liver health. Fifty adults aged 35-45 with fatty liver will be split into two groups: one gets the diet plus TENS, the other gets the diet alone. Researchers will measure changes in appetite, liver enzymes, and body weight over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcutaneous electrical nerve stimulation (TENS) device
What this could lead to
If it works, this could offer a non-drug way to help manage appetite and liver health in people with fatty liver disease.
What could go wrong
This is a small, early-stage trial with only 50 participants. The results may not apply to everyone, and TENS may not provide meaningful benefits beyond diet alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 45 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The age will range from 35-45 years old. * BMI (Body Mass Index 30-34.9 kg/m2.) * With fatty liver infiltration confirmed by abdominal ultrasound * Elevated of liver enzymes as a primary marker * All patients are psychologically stable. Exclusion Criteria: * History of cardiovascular or respiratory disease. * If any known endocrine diseases e.g. Hypothyroidism (which elevates liver enzymes and effects on appetite) * Any acute or chronic illness causing elevated liver enzymes other than fatty liver e.g. Hepatitis b, Hepatitis c * Any neurological illness or impairment can effect on sensation * Patients associated with infections, mental or malignant conditions. * Patients who have undergone any gastric surgery e.g. Bariatric surgery * Taking dietary supplement for weight reduction. * Patients who participating in any other exercise program.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonalcoholic fatty liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonalcoholic fatty liver

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Internal Medicine Hospital Cairo University

    Giza, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.